Amgen shares are up about 24% this year on interest in its obesity candidate MariTide. One bearish take flags manufacturing scale and a crowded GLP-1 market.
Recap by typeshit. Full story at Simply Wall Street.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Lilly closed at $1,169.60, and one widely followed narrative pegs fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Fiber, protein, berberine and curcumin get a look, though experts quoted say none come close to the effect of prescription GLP-1 drugs.
Loading…